title: Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.
abstract: BACKGROUND
  Acquired C1-inhibitor (C1-inh) deficiency is usually associated with the presence of circulating C1-inh autoantibodies. These autoantibodies have been shown previously to bind to two synthetic peptides corresponding to C1-inh amino acid residues 438-449 (peptide 2) and 448-459 (peptide 3) but not to peptide 1 (residues 428-440).
  
  
  METHODS
  Affinity-purified C1-inh autoantibodies from two patients with acquired C1-inh deficiency were studied for their effects on the inhibition of C1s activity by C1-inh using SDS-PAGE and hydrolysis of a synthetic ester.
  
  
  RESULTS
  Functional studies confirmed that the anti-C1-inh autoantibodies abrogated C1-inh activity, and their maximum effect was produced when the concentrations of C1-inh and autoantibody were approximately equimolar. The autoantibodies prevent the formation of the C1s-C1-inh complex, but they do not dissociate the preformed complex, suggesting that the autoantibodies act prior to the formation of the enzyme-inhibitor complex. In the presence of autoantibodies, C1s cleaves C1-inh, and a stable covalent bond between C1s and C1-inh does not form. Peptides 2 and 3, but not peptide 1 inhibited autoantibody activity, thus C1-inh inhibitory activity for C1s was expressed fully.
  
  
  CONCLUSIONS
  Our data indicate that the anti-C1-inh autoantibodies convert C1-inh to a substrate by preventing the formation of the stable covalent protease-serpin complex. The data also suggest a possible therapeutic use for peptides 2 and 3 or their derivatives in the management of patients with type II acquired angioedema (AAE).
authors.affiliation: Department of Microbiology and Immunology, University of Leicester, Leicester, U.K.
authors.forename: S
authors.initials: S
authors.lastname: He
authors.forename: R B
authors.initials: RB
authors.lastname: Sim
authors.forename: K
authors.initials: K
authors.lastname: Whaley
mesh_terms: D001323:Autoantibodies / Q000276:immunology*; D003174:Complement C1 Inactivator Proteins / Q000276:immunology* / Q000378:metabolism*; D003173:Complement C1s / Q000378:metabolism*; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000276:immunology; D007700:Kinetics; D046911:Macromolecular Substances; D008297:Male; D008875:Middle Aged; D011485:Protein Binding / Q000276:immunology
chemical_list: D001323:Autoantibodies; D003174:Complement C1 Inactivator Proteins; D046911:Macromolecular Substances; D003173:Complement C1s